Build your base

Alienum phaedrum torquatos nec eu, vis detraxit periculis ex, nihil expetendis in mei. Mei an pericula euripidis, hinc partem ei est.

Barry Mangum, PharmD

New Horizon / Barry Mangum, PharmD

Barry Mangum, PharmD

CEO, Paidion Research

ABOUT

Dr. Mangum is a leader in pediatric clinical pharmacology and drug development. He has been instrumental in developing multiple compounds for the care of children worldwide. His expertise is in neonatal pharmacology where he has excelled in understanding the pharmacology and pathophysiology of disease in the most vulnerable patients, the neonate. He also has served as an academic with appointments in the Schools of Medicine at Duke University and University of North Carolina-Chapel Hill as Associate Clinical Professor, Clinical Pharmacology and Associate Clinical Professor, Pediatrics.  He is a graduate of The Medical University of South Carolina where he received his Doctorate in Pharmacy with special thesis emphasis on neonatal/pediatric pharmacology.  Currently, Dr. Mangum is a co-founders and CEO of a pediatric CRO, Paidion Research, Inc. dedicated to the excellence in pediatric clinical research. Dr. Mangum has an extensive background in neonatal and pediatric pharmacology and is the co-founder, co-author, and co-publisher of the leading drug dosing manual, NeoFax®: A Manual of Drugs Used in Neonatal Care. NeoFax® has been globally published and distributed for twenty-eight year as a source for neonatal drug dosing information. The NeoFax® content has been integrated into varying intranet and handheld device application to aid in drug information and dose calculations (e.g. NeoFax-EM, NeoFax-Rx, and NeoFax-PN). Dr. Mangum has been strategically involved with the design and the implementation of all clinical and business decisions related to the NeoFax® endeavors.  Both the software and the publishing companies, Neofax-PC, Inc. and Acorn Publishing, Inc. were sold to Thomson Reuters in 2007.Dr. Mangum continues to be active in national and global leadership of pediatric clinical research as an educator and committee member of academic and pharmaceutical industry organizations.  He has represented the interest of pediatric patients by chairing and speaking at meetings globally on the topic of neonatal pharmacology and legislative issues to support clinical research in children.  Additionally, Dr. Mangum has recently completed serving a four-year appointment to the World Health Organization’s Expert Committee on the Selection and Use of Essential Medicines.

WEBSITE

https://www.paidion.com/

SESSION

Oct 29th 9:00AM ET Panelist Session 3 – Neonatal Research Insights